Novel gene-silencing therapeutics for multidrug-resistant gram-negative pathogens
针对多重耐药革兰氏阴性病原体的新型基因沉默疗法
基本信息
- 批准号:8823180
- 负责人:
- 金额:$ 37.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-05-01 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acinetobacter baumanniiAlgorithmsAmericasAmpicillinAnimal ModelAnimalsAnti-Bacterial AgentsAntibiotic ResistanceAntibiotic-resistant organismAntibioticsBacteremiaBacteriaBacterial GenesBindingBurkholderia cepacia complexClinicalClinical ResearchCommunicable DiseasesDatabasesDevelopmentEscherichia coliEssential GenesFatty AcidsFutureGene SilencingGene TargetingGenesGoalsGram-Negative BacteriaGrowthHospitalsHumanIn VitroInfectionInflammationLeadLipopolysaccharide Biosynthesis PathwayMinimum Inhibitory Concentration measurementMorbidity - disease rateMulti-Drug ResistanceMusOrganismPathway interactionsPeptidesPeptidoglycanPharmaceutical PreparationsPhasePredispositionRNAResistanceRoleSalmonellaSalmonella typhimuriumSocietiesTechnologyTestingTherapeuticTherapeutic AgentsTherapeutic Usesabstractingantimicrobialbacterial resistancebactericidebasebeta-Lactam Resistancedesignfightingimprovedin vivokillingsmortalitymouse modelnovelnovel strategiespathogenphosphorodiamidate morpholino oligomerpre-clinicalresistance mechanismsynthetic constructtherapeutic developmenttherapeutic target
项目摘要
Project Summary/Abstract
The need for new antimicrobials is increasingly urgent. The rate of multidrug resistant pathogens continues to
increase leading to significant morbidity and mortality throughout the world. Furthermore, the current pipeline
for new antimicrobials remains very narrow. The Infectious Diseases Society of America has identified in their
"Bad Bugs, No Drugs" campaign, a group of pathogens that have become increasingly resistant to current
antibiotics. This group includes the Gram-negative pathogens Acinetobacter baumannii and Escherichia coli.
A new paradigm in antibiotic discovery and design has recently been shown effective against numerous
bacteria. This new approach is based on a platform technology called peptide-phosphorodiamidate mopholino
oligomers (PPMOs). PPMOs are synthetic DNA mimics that bind to RNA in a sequence-specific, antisense
manner and inhibit expression of essential bacterial genes. PPMOs have already been used successfully to kill
a variety of bacterial pathogens including the Gram-negative bacteria Escherichia coli, Salmonella
typhimurium, Burkholderia cepacia complex and Acinetobacter baumannii. PPMOS are bactericidal in culture,
and reduce bacteremia and improve survival in animal models of infection. PPMOs are more potent than
many traditional antibiotics such as ampicillin. The goal of this project is to develop PPMOs for therapeutic
use against the multidrug resistant pathogens Escherichia coli and Acinetobacter baumannii. The specific
aims are to design, produce and screen PPMOS against various gene targets in the multidrug-resistant
pathogens E. coli and A. baumannii. The experimental approach is to target genes in pathways that are
known or suspected to be essential for the growth of the organism, including genes for biosynthesis of
lipopolysaccharide, peptidoglycan, and fatty acids. Another approach will be to use PPMOs as adjunctive
therapies and target specific antibiotic resistance mechanisms in order to restore susceptibility to currently
used antibiotics. This technology provides a methodological advantage because many PPMOs can be rapidly
synthesized and simultaneously tested against numerous targets. This allows for the possibility of targeting
multiple genes in a single organism or the development of cocktails of PPMOs that target multiple pathogens.
This project will identify lead target PPMOs in E. coli and A. baumannii that can be moved forward to pre-
clinical and clinical studies.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Elihu Greenberg其他文献
David Elihu Greenberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Elihu Greenberg', 18)}}的其他基金
Antibiotic Resistance Determination Utilizing Machine Learning
利用机器学习确定抗生素耐药性
- 批准号:
10442982 - 财政年份:2022
- 资助金额:
$ 37.21万 - 项目类别:
Antibiotic Resistance Determination Utilizing Machine Learning
利用机器学习确定抗生素耐药性
- 批准号:
10663905 - 财政年份:2022
- 资助金额:
$ 37.21万 - 项目类别:
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa
铜绿假单胞菌基因沉默疗法的开发
- 批准号:
10203746 - 财政年份:2019
- 资助金额:
$ 37.21万 - 项目类别:
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa
铜绿假单胞菌基因沉默疗法的开发
- 批准号:
10451560 - 财政年份:2019
- 资助金额:
$ 37.21万 - 项目类别:
Gene silencing therapeutics for chronic infections in cystic fibrosis
囊性纤维化慢性感染的基因沉默疗法
- 批准号:
8511030 - 财政年份:2013
- 资助金额:
$ 37.21万 - 项目类别:
Gene silencing therapeutics for chronic infections in cystic fibrosis
囊性纤维化慢性感染的基因沉默疗法
- 批准号:
9248236 - 财政年份:2013
- 资助金额:
$ 37.21万 - 项目类别:
Gene silencing therapeutics for chronic infections in cystic fibrosis
囊性纤维化慢性感染的基因沉默疗法
- 批准号:
9039523 - 财政年份:2013
- 资助金额:
$ 37.21万 - 项目类别:
Novel gene-silencing therapeutics for multidrug-resistant gram-negative pathogens
针对多重耐药革兰氏阴性病原体的新型基因沉默疗法
- 批准号:
9055626 - 财政年份:2012
- 资助金额:
$ 37.21万 - 项目类别:
Novel gene-silencing therapeutics for multidrug-resistant gram-negative pathogens
针对多重耐药革兰氏阴性病原体的新型基因沉默疗法
- 批准号:
8842086 - 财政年份:2012
- 资助金额:
$ 37.21万 - 项目类别:
Novel gene-silencing therapeutics for multidrug-resistant gram-negative pathogens
针对多重耐药革兰氏阴性病原体的新型基因沉默疗法
- 批准号:
8267916 - 财政年份:2012
- 资助金额:
$ 37.21万 - 项目类别:
相似海外基金
CAREER: Blessing of Nonconvexity in Machine Learning - Landscape Analysis and Efficient Algorithms
职业:机器学习中非凸性的祝福 - 景观分析和高效算法
- 批准号:
2337776 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Continuing Grant
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
- 批准号:
2338816 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Continuing Grant
CAREER: Structured Minimax Optimization: Theory, Algorithms, and Applications in Robust Learning
职业:结构化极小极大优化:稳健学习中的理论、算法和应用
- 批准号:
2338846 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Continuing Grant
CRII: SaTC: Reliable Hardware Architectures Against Side-Channel Attacks for Post-Quantum Cryptographic Algorithms
CRII:SaTC:针对后量子密码算法的侧通道攻击的可靠硬件架构
- 批准号:
2348261 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Standard Grant
CRII: AF: The Impact of Knowledge on the Performance of Distributed Algorithms
CRII:AF:知识对分布式算法性能的影响
- 批准号:
2348346 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Standard Grant
CRII: CSR: From Bloom Filters to Noise Reduction Streaming Algorithms
CRII:CSR:从布隆过滤器到降噪流算法
- 批准号:
2348457 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Standard Grant
EAGER: Search-Accelerated Markov Chain Monte Carlo Algorithms for Bayesian Neural Networks and Trillion-Dimensional Problems
EAGER:贝叶斯神经网络和万亿维问题的搜索加速马尔可夫链蒙特卡罗算法
- 批准号:
2404989 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Standard Grant
CAREER: Efficient Algorithms for Modern Computer Architecture
职业:现代计算机架构的高效算法
- 批准号:
2339310 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Continuing Grant
CAREER: Improving Real-world Performance of AI Biosignal Algorithms
职业:提高人工智能生物信号算法的实际性能
- 批准号:
2339669 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Continuing Grant
DMS-EPSRC: Asymptotic Analysis of Online Training Algorithms in Machine Learning: Recurrent, Graphical, and Deep Neural Networks
DMS-EPSRC:机器学习中在线训练算法的渐近分析:循环、图形和深度神经网络
- 批准号:
EP/Y029089/1 - 财政年份:2024
- 资助金额:
$ 37.21万 - 项目类别:
Research Grant














{{item.name}}会员




